Alphatec : Third quarter 2020 financial results presentation

Q3 2020 FINANCIAL RESULTS

Pat Miles, Chairman and CEO - November 5, 2020

FORWARD LOOKING STATEMENTS

Alphatec cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of assumptions, risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company cautions investors that there can be no assurance that actual results will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include, but are not limited to: references to the Company's revenue and future outlook; planned product launches, introductions, regulatory submissions or clearances; efforts to transform sales and distribution channels; and the Company's future ability to finance its operations and sufficiency of its cash runway. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to: the uncertainty of success in developing new products or products currently in the pipeline; the uncertainties in the Company's ability to execute upon its strategic operating plan; the uncertainties regarding the ability to successfully license or acquire new products, and the commercial success of such products; failure to achieve acceptance of the Company's products by the surgeon community; failure to obtain FDA or other regulatory clearance or approval or unexpected or prolonged delays in the process; continuation of favorable third party reimbursement; unanticipated expenses or liabilities or other adverse events affecting cash flow or the Company's ability to control its costs or achieve profitability; uncertainty of additional funding; the Company's ability to compete with other products or with emerging technologies; product liability exposure; an unsuccessful outcome in any litigation; patent infringement claims; claims related to the Company's intellectual property; the Company's ability to meet its financial obligations; future strategic and/or financing collaborations between the Company and any third-party and potential benefits or synergies resulting therefrom; and the impact of the COVID-19 pandemic on the Company's business and financial results and recovery of the spine market. A further list and description of these and other factors, risks and uncertainties can be found in the Company's most recent annual report, and any subsequent quarterly and current reports, filed with the Securities and Exchange Commission. ATEC disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.

2

HIGHLIGHTS

Outpaced the industry (again) with >40% revenue growth in Q3 2020

Follow-on offering creates runway to execute growth initiatives

Continued approach-based new products will continue to drive long-term growth

3

Q3 2020 SCORECARD

The momentum we are building is STRONG

>40%

>70%

8th

YoY U.S. revenue growth

New product revenue

contribution vs 42% in Q3 2019 and <10% in FY2018

Consecutive quarter of

double-digit YoY growth

20%

13%

1.8

YoY growth in revenue

per surgeon

YoY growth in average revenue per case; up 32%

since Q3 2018

Average product categories sold per case

4